Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering – Do patient characteristics warrant precision engineering?

B. J. de Kort, S. E. Koch, T. B. Wissing, M. M. Krebber, C. V.C. Bouten*, A. I.P.M. Smits

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

30 Citations (Scopus)
115 Downloads (Pure)


In situ tissue engineering using bioresorbable material implants - or scaffolds - that harness the patient's immune response while guiding neotissue formation at the site of implantation is emerging as a novel therapy to regenerate human tissues. For the cardiovascular system, the use of such implants, like blood vessels and heart valves, is gradually entering the stage of clinical translation. This opens up the question if and to what extent patient characteristics influence tissue outcomes, necessitating the precision engineering of scaffolds to guide patient-specific neo-tissue formation. Because of the current scarcity of human in vivo data, herein we review and evaluate in vitro and preclinical investigations to predict the potential role of patient-specific parameters like sex, age, ethnicity, hemodynamics, and a multifactorial disease profile, with special emphasis on their contribution to the inflammation-driven processes of in situ tissue engineering. We conclude that patient-specific conditions have a strong impact on key aspects of in situ cardiovascular tissue engineering, including inflammation, hemodynamic conditions, scaffold resorption, and tissue remodeling capacity, suggesting that a tailored approach may be required to engineer immuno-regenerative biomaterials for safe and predictive clinical applicability.

Original languageEnglish
Article number113960
Number of pages30
JournalAdvanced Drug Delivery Reviews
Publication statusPublished - Nov 2021

Bibliographical note

Funding Information:
This research was financially supported by the Gravitation Program “Materials Driven Regeneration”, funded by the Netherlands Organization for Scientific Research (024.003.013) and by the InSiTeVx project (436001003); financially supported by ZonMw within the LSH 2Treat Programme and the Dutch Kidney Foundation.

Publisher Copyright:
© 2021 The Authors


Dive into the research topics of 'Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering – Do patient characteristics warrant precision engineering?'. Together they form a unique fingerprint.

Cite this